Product Profiles

Article

A round-up of the latest ophthalmic products

Ocular surface interferometer

TearScience has announced broadened indication for use of the LipiView Ocular Surface Interferometer.

Please visit http://www.tearscience.com/ for more information

Single-use adjustable trephine

Building on its experience, Moria has introduced a new Single-Use Adjustable Vacuum Trephine.

Designed to produce straight-walled cuts, the adjustable trephine features an adjustment ring enabling setting the blade descent depth. Its centration indicator ensures no parallax errors.

Moreover, its vacuum surface is 3 times more efficient than a standard trephine and its limbal suction features a central cornea support design for a perfect conformation to the cornea.

This trephine can be used on a Moria Single-Use Artificial Chamber to cut the donor cornea from the epithelial side, which allow the reduction of the shape disparity and may induce less astigmatism.

Visit http://www.moria-surgical.com/ for more details.

Non-contact tonometer

Corvis ST, a new non-contact tonometer with an ultra-high-speed Scheimpflug camera that can visualize the reaction of the cornea on air impulse, is now available from Oculus.

The company reports that this instrument has the potential to determine a highly accurate value of IOP that is close to the 'true IOP', based on the measured IOP, the biomechanical properties and the corneal thickness.

Additionally, screening for corneal ectasia and visualizing the effect of CXL is possible with the Corvis. The system can monitor changes of the deformation response of the cornea and as such enables the user to distinguish between normal and ectatic corneas, as well as quantifying the effect of CXL.

Please visit http://www.oculus.de/corvis-st/ for further details.

Continuous IOP monitoring

Patients can wear the IOL for up to 24 hours and can perform every day activities, including sleeping. An adhesive antennae is worn around the eye and is connected to a portable recording device.

The data collected from the device is then transferred to the practitioner's computer for analysis. This complements punctual tonometer readings to offer a qualitative profile of a patient's IOP and thus optimization of glaucoma management.

Go to http://www.sensimed.ch/ for further details.

Internal limiting membrane dye

The non-toxic and biocompatible dye selectively stains the ILM, enabling the clear distinction between underlying retinal tissues and epiretinal membranes.

Brilliant Peel sinks onto the required surface in the liquid-filled eye and does not mix with rising agents. The removal of the ILM is safe, precise and non-traumatic.

Visit http://www.geuder.de/ for more information

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.